Headquartered in Austin, Texas, MED AI Diagnostics, LLC (MED AI DX) is a trusted partner in neurodiagnostic pathology services. Our primary specialization is in Epidermal Nerve Fiber Density (ENFD) testing, a groundbreaking diagnostic tool that aids physicians in the detection and diagnosis of small fiber neuropathy. By providing unparalleled expertise and cutting-edge technology, we empower healthcare professionals to deliver accurate and timely diagnoses for their patients.
At MED AI DX, our mission is to advance neurodiagnostic pathology by providing precise, reliable, and innovative diagnostic solutions. We strive to enhance patient care by equipping physicians with the tools they need to understand and address complex neuropathic conditions.
At MED AI Diagnostics, LLC, we are redefining excellence in ENFD diagnostic testing through our proprietary methods, expert team, and patient-centered approach. Here’s why healthcare providers nationwide trust MED AI DX:
Med Ai Dx’s proprietary method for ENFD diagnostic testing utilizes immunohistochemical (IHC) staining in addition to H&E staining for diagnosis. Other commercial diagnostic laboratories often rely on multiple IHC staining processes for all elements of ENFD processing, which can result in higher charges to patients and the healthcare system. Through our method, Med Ai Dx pathologists can examine tissue sections for more than just small nerve fibers and their density. The H&E background stain better highlights additional abnormalities, such as inflammatory cells, vasculitis, sweat glands, or subtle tumors. This comprehensive evaluation ensures that the ordering provider receives the most complete information to treat small fiber sensory neuropathy and other identified underlying causes. If a concerning abnormality is identified, it can be promptly reported and communicated to the ordering provider. Our validated ENFD protocol enhances diagnostic yield, improves outcomes, and does not require additional CPT codes or unnecessary costs to the patient.
Our team of highly skilled pathologists and neurodiagnostic specialists are dedicated to delivering precise, insightful, and actionable results. With their expertise, providers can confidently diagnose and manage neuropathic conditions.
With a national presence, MED AI DX partners with physicians and healthcare organizations across the country, ensuring seamless access to our diagnostic services and support.
We continually leverage state-of-the-art technology and advanced diagnostic methods to uphold the highest standards of care. Our dedication to innovation positions us at the forefront of neurodiagnostic pathology. Additionally, we remain responsive to evolving medical literature, academic advancements, and payor policy updates, ensuring our diagnostic methods and services are both cutting-edge and compliant.
At MED AI DX, every test result contributes to improved patient outcomes. By facilitating early diagnosis and comprehensive evaluation, we help providers deliver personalized treatment plans that enhance patients' quality of life.
By choosing MED AI DX, you are partnering with a leader in diagnostic excellence. Together, we can advance the understanding and treatment of small fiber neuropathy and other neuropathic conditions.
Epidermal Nerve Fiber Density (ENFD) testing is a minimally invasive and highly specialized diagnostic procedure used to measure the density of small nerve fibers in the skin. These small nerve fibers extend from the papillary dermis into the skin’s epidermis, or surface epithelium, playing a vital role in sensory functions. ENFD testing is the recognized gold-standard diagnostic tool for assessing small fiber peripheral neuropathy, a condition that can manifest as chronic pain, burning sensations, or numbness.
By quantifying and evaluating the integrity of the terminal branches of peripheral nerves within the epidermis, ENFD testing provides objective evidence of small fiber damage. A diminished number of these small nerve fibers signals established nerve damage or disease, with lower counts correlating to more severe damage or advanced disease stages.
ENFD testing empowers healthcare providers by offering critical insights into the underlying causes of neuropathic symptoms, helping them address and manage these conditions effectively. As a trusted and widely recognized diagnostic tool, ENFD testing is a cornerstone in advancing care for patients with small fiber neuropathy.
The biopsy is minimally invasive and performed using a 3 mm punch tool. The patient’s skin is anaesthetized with 2% lidocaine with epinephrine, which alleviates the pain during the biopsy. The collection takes the provider approximately 90 seconds to perform, with the entire procedure taking about 10-15 minutes. Samples are placed in Zamboni fixative and shipped in pre-paid packaging. The biopsy sites are covered with a bandage and do not require any special treatment.
At MED AI Diagnostics, we pride ourselves on delivering a comprehensive and seamless diagnostic experience to our clients. Our range of services is designed to support healthcare providers at every step of the diagnostic journey:
At MED AI DX, we strive to make the most advanced diagnostic testing both accessible and affordable. Our billing policy is guided by the 4 C’s to ensure a transparent and patient-centered approach:
Whether you’re a provider seeking diagnostic solutions or a patient looking for more information, our team is ready to support you at every step.
We’re here to assist you. Connect with us for any questions, support, or to learn more about our services:
Copyright © 2024 Med Aidx. All Rights Reserved.